Ipamorelin: Complete Growth Hormone Secretagogue Research Profile
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively stimulates growth hormone release from the anterior pituitary gland. It is considered one of the most selective GHRPs, with minimal impact on cortisol, prolactin, and appetite — making it a preferred research compound for studying GH-axis physiology.
Molecular Profile
| Parameter | Specification |
|---|---|
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
| Molecular Formula | C₃₈H₄₉N₉O₅ |
| Molecular Weight | 711.85 g/mol |
| CAS Number | 170851-70-4 |
| Receptor Target | GHS-R1a (Ghrelin receptor) |
| Half-Life | ~2 hours |
| Storage | -20°C lyophilized; 2-8°C reconstituted |
Mechanism of Action
Ipamorelin binds to the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin. However, unlike ghrelin and other GHRPs, ipamorelin demonstrates remarkable selectivity for GH release without significantly affecting ACTH (and therefore cortisol), prolactin levels, or appetite stimulation. This selectivity is attributed to its unique pentapeptide structure.
The GH release triggered by ipamorelin follows a dose-dependent, bell-shaped curve. It works synergistically with GHRH analogs like CJC-1295 (Mod GRF 1-29), as GHRH and GHRP activate complementary pathways — GHRH via the GHRH receptor and ipamorelin via GHS-R1a.
Ipamorelin vs Other GHRPs
| Feature | Ipamorelin | GHRP-6 | GHRP-2 | Hexarelin |
|---|---|---|---|---|
| GH Release | Moderate | Strong | Strong | Strongest |
| Cortisol Impact | None | Mild increase | Mild increase | Moderate increase |
| Prolactin Impact | None | Mild increase | Moderate increase | Strong increase |
| Appetite Stimulation | None | Strong | Moderate | None |
| Desensitization | Minimal | Moderate | Moderate | High |
| Selectivity | Highest | Low | Moderate | Low |
Key Research Areas
Body Composition Research
Studies in animal models have shown ipamorelin promotes lean body mass increases, fat mass reduction particularly visceral adipose tissue, improved body composition ratios, and dose-dependent effects on growth parameters.
Bone Density Research
Ipamorelin has been studied for its effects on bone metabolism. Research in ovariectomized rat models (a standard osteoporosis model) demonstrated increased bone mineral content, improved bone formation markers, and enhanced periosteal bone formation.
Post-Surgical Recovery Research
Clinical trials have investigated ipamorelin for post-operative ileus (POI) — delayed bowel function after abdominal surgery. Phase II studies showed potential for accelerating gastrointestinal recovery.
Ipamorelin + CJC-1295 Combination
The most commonly studied combination protocol pairs ipamorelin with CJC-1295 without DAC (Mod GRF 1-29). This combination leverages two complementary pathways for amplified GH release. CJC-1295 stimulates via the GHRH receptor while ipamorelin activates GHS-R1a, creating a synergistic effect that produces greater GH output than either peptide alone.
Research-Grade Ipamorelin from Aarise Healthcare
Aarise Healthcare supplies high-purity ipamorelin (≥98% HPLC) for qualified research institutions. Browse our catalog or contact us for pricing and availability.
Related Articles
- AOD-9604 Peptide Research Guide — Mechanism, Studies & Applications
- BPC-157 Peptide Research Guide — Mechanism, Studies & Laboratory Applications
- PEG-MGF (Mechano Growth Factor) Research Guide — Mechanism, Studies & Protocols
- Melanotan 2 Research Guide — Mechanism of Action, MC4R Agonist Studies & Protocols
Also from Aarise Group:
